FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

【プレスリリースメモ】 RNAi関係 (2013.7.2)  

<Alnylam Pharmaceuticals>
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)(2013.6.30)
Alnylam to Webcast Presentation at 8th Annual JMP Securities Healthcare Conference(2013.7.1)
Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders(2013.7.2)

<Mesoblast>
MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy(2013.6.26)

<Benitec>
Benitec to Present to Bioshares Biotech Summit(2013.6.21)

<CytRx Corporation>
CytRx Reaches Enrollment Target in International Phase 2b Clinical Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma(2013.6.24)

<Dicerna Pharmaceuticals>
Dicerna Announces Additional Patent Claims Allowed, Broadening Coverage of Extended Dicer Substrate Therapeutic Structures(2013.7.1)

<Dynavax Technologies>
Dynavax to Present at the JMP Securities Healthcare Conference(2013.7.2)

<Exiqon A/S>
Exiqon A/S - Exiqon launches LNA™ microRNA Target Site Blockers(2013.6.27)

<Galena Biopharma>
Galena Biopharma to Present at the 8th Annual JMP Securities Healthcare Conference(2013.7.2)

<Generex Biotechnology>
Generex Announces Conference Call with Members of the Antigen Express Scientific Advisory Board(2013.7.1)

<Genethon>
The European charity Myotubular Trust is supporting Généthon in developing gene therapy for myotubular myopathy(2013.6.24)
Généthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer(2013.6.27)

<Idera Pharmaceuticals>
Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases(2013.7.1)

<Isis Pharmaceuticals>
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes(2013.6.23)
Breaux Castleman Joins Isis Pharmaceuticals' Board of Directors(2013.6.25)
Isis Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference(2013.7.2)

<Lorus Therapeutics>
LORUS THERAPEUTICS APPOINTS DR. BRAD THOMPSON, AN EXPERIENCED BIOTECHNOLOGY PROFESSIONAL, TO THE BOARD OF DIRECTORS(2013.6.27)

<Mirna Therapeutics>
Mirna Therapeutics and Horizon Discovery Publication Elucidates Novel miR-34 Tumor Suppressor Pathway, Underscores miR-34 as Important Anticancer Approach(2013.6.26)

<Moderna Therapeutics>
Peter Haeberli, Esq. has joined Moderna as Senior Vice President, Intellectual Property and Legal Affairs(2013.7.1)

<Sarepta Therapeutics>
Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference(2013.7.2)

<Silence Therapeutics>
・Cancellation of Warrants(2013.7.3)

<Tekmira Pharmaceuticals>
Tekmira's LNP Technology Enables Alnylam's Positive Phase II ALN-TTR02 Data(2013.7.1)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares(2013.6.24)
Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes(2013.6.27)
Medicis Announces Five-Year Aesthetic Collaboration with Mentor(2013.7.2)

<Vical>
Vical and Astellas Announce Initiation of Phase 3 Trial of ASP0113 Cytomegalovirus Vaccine(2013.6.25)
Vical to Present at JMP Securities Healthcare Conference(2013.7.3)

<アンジェスMG>
NF-κBデコイオリゴを用いたアトピー性皮膚炎治療薬の第I相臨床試験開始について(2013.6.24)
虚血性疾患治療剤「コラテジェン」の小規模臨床試験の開始に向けNIHにおけるRACにレビュー申請(2013.6.27)
抗菌、抗真菌作用をもつ新規ペプチドの物質特許が成立(米国)-幅広い抗菌スペクトルを有する抗菌剤、抗真菌剤、消毒剤への活用-(2013.7.1)


スポンサーサイト
[ 2013/07/03 20:00 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!